Concurrent 5-fluorouracil, mitomycin C and radiation with or without brachytherapy in recurrent cervical cancer: A scoring system to predict clinical response and outcome

Tumori

Volumn 91, Issue 4, 2005, Pages 295-301

  Smaniotto, Daniela ^a   D'Agostino, Giuseppe ^a   Luzi, Stefano ^a   Valentini, Vincenzo ^a   Macchia, Gabriella ^a   Mantini, Giovanna ^a   Margariti, Pasquale Alessandro ^a   Ferrandina, Gabriella ^a   Scambia, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cervical cancer; Chemoradiation; Local recurrence; Prognostic score

Indexed keywords

FLUOROURACIL; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; ENTEROPATHY; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOPENIA; LYMPH NODE; PHASE 2 CLINICAL TRIAL; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; RADIATION DOSE; RECURRENT CANCER; RISK FACTOR; SALVAGE THERAPY; SCORING SYSTEM; SKIN TOXICITY; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER; VAGINA DISEASE; VAGINA STENOSIS;

EID: 26444457322     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160509100402     Document Type: Article

References (40)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics 2004. Cancer J Clin, 54: 8-29, 2004.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189: 12-19, 1999.
3. Vermorken JB: The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review. Int J Gynecol Cancer, 3: 129-142, 1993.
4. Friedlander M: Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist, 7: 342-347, 2002.
5. Waggoner SE: Cervical cancer. Lancet, 361: 2217-2225, 2003.
6. Jobsen JJ, Leer JWH, Cleton FJ, Hermans J: Treatment of locoregional recurrence of carcinoma of the cervix by radiotherapy after primary surgery. Gynecol Oncol, 33: 368-371, 1989.
7. Tan R, Chung CH, Liu MT, Lai YL, Chang KH: Radiotherapy for postoperative recurrent uterine cervical carcinoma. Acta Oncol, 30: 353-356, 1991.
8. Ito H, Shigematsu N, Kawada T, Kubo A, Isobe K, Kara R, Yasuda S, Aruga T, Ogata H: Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy. Gynecol Oncol, 67: 154-161, 1997.
9. Ijaz T, Eifel PJ, Burke T, Oswald MJ: Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma. Gynecol Oncol, 70: 241-246, 1998.
10. Estape R, Angioli R: Surgical management of advanced and recurrent cervical cancer. Semin Surg Oncol, 16: 236-241, 1999.
11. Selman AE, Copeland LJ: Surgical management of recurrent cervical cancer. Yonsei Med J, 43: 754-762, 2002.
12. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Eng J Med, 340: 1137-1143, 1999.
13. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Eng J Med, 340: 1144-1153, 1999.
14. Keys HM, Bundy BN, Steheman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med, 340: 1154-1161, 1999.
15. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao SY: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol, 17: 1339-1348, 1999.
16. Peters WA 3rd, Liu PY, Barret RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol, 18: 1606-1613, 2000.
17. NCI Clinical Announcement. Bethesda MD, US Dept of Health and Human Services, Public Health Service, February 1999.
18. Nigro ND, Vaitnevicius VK, Considine B: Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum, 17: 354-356, 1974.
19. Radiation Therapy Oncology Group morbidity scoring criteria. www.rtog.org/members/toxicity/main.html
20. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
21. Kaplan FL, Meier P: Non parametric estimation from incomplete observations. Am J Stat Assoc, 53: 457-481, 1958.
22. Peto R, Peto J: Asymptomatically efficient rank invariant procedures. J R Stat Soc, 135: 185-207, 1972.
23. Cox DR: Regression model and life tables. J Royal Stat Soc Series B, 34: 187-220, 1972.
24. Thomas GM, Dembo AJ, Black B, Bean HA, Beale FA, Pringle JR, Rawlings G, Depetrillo D: Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery. Gynecol Oncol, 27: 254-263, 1987.
25. Martinez Monge R, Jurado M, Azinovic I, Aristu J, Fernandez-Hidalgo O, Lopez G, Calvo FA: Preoperative chemoradiation and adjuvant surgery in locally advanced or recurrent cervical carcinoma. Rev Med Univ Navarra, 41: 19-26, 1997.
26. Maneo A, Landoni F, Cormio G, Colombo A, Mangioni C: Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma. Ann Oncol, 10: 803-807, 1999.
27. Million RR, Zimmerman RC: Evaluation of University of Florida split-course technique for various head and beck squamous cell carcinomas. Cancer, 35: 1533-1536, 1975.
28. Budihna M, Skrk J, Smid L, Furlan L: Tumor cell repopulation in the rest interval of split-course radiation treatment. Strahlentherapie, 156: 402-408, 1980.
29. Cummings BJ, Keane TJ, O'Sullivan MB, Wong CS, Catton CN: Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys, 21: 1115-1125, 1991.
30. Albrecht GL, Devlieger PJ: The disability paradox: high quality of life against all odds. Soc Sci Med, 48: 977-988, 1999.
31. Sprangers MAG, Schwartz CE: Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med, 48: 1507-1515, 1999.
32. Smaniotto D, Luzi S, Morganti AG, Cellini N: Prognostic significance of anemia and role of erythropoietin in radiation therapy. Tumori, 86: 17-23, 2000.
33. Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr, Coia LR: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol, 13: 2077-2083, 1995.
34. Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, Brugere J, Point D, Giraud P, Cosset JM: Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology, 201: 553-558, 1996.
35. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer, 86: 1528-1536, 1999.
36. Lorvidhaya V, Chitapanarux I, Sangruchi S, Lertsanguansinchai P, Kongthanarat Y, Tangkaratt S, Visetsiri E: Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. Int J Radiat Oncol Biol Phys, 55: 1226-1232, 2003.
37. Pras E, Willemse PH, Canrinus AA, de Bruijn HW, Sluiter WJ, ten Hoor KA, Aalders JG, Szabo BG, de Vries EG: Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment. Int J Radiat Oncol Biol Phys, 52: 23-32, 2002.
38. Ferrandina G, Ranelletti FO, Legge F, Gessi M, Salutari V, Distefano MG, Lauriola L, Zannoni GF, Martinelli E, Scambia G: Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer. Clin Cancer Res, 10: 3117-3123, 2004.
39. Curran WJ: New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology, 63: 29-38, 2002.
40. Toita T, Kakinohana Y, Ogawa K, Adachi G, Moromizato H, Nagai Y, Maehama T, Sakumoto K, Kanazawa K, Murayama S: Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule. Int J Radiat Oncol Biol Phys, 56: 1344-1353, 2003.